Cargando…
Review of Implant Gonadotrophin-Releasing Hormone Agonist Use: Experience in a Single Academic Center
BACKGROUND: Gonadotrophin-releasing hormone agonists (GnRHas) are used for puberty suppression in central precocious puberty (CPP) and gender dysphoria (GD). Guidelines on biochemical monitoring are not defined. OBJECTIVES: The aim of this study was to evaluate the utility of biochemical monitoring...
Autores principales: | Ni, Jennifer, Chi, Carolyn, Aye, Tandy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614268/ https://www.ncbi.nlm.nih.gov/pubmed/36791687 http://dx.doi.org/10.1159/000529733 |
Ejemplares similares
-
Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders
por: Xia, Min, et al.
Publicado: (2021) -
Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
por: Chung, Seung Ah, et al.
Publicado: (2021) -
The effect of gonadotrophin-releasing hormone agonist versus human chorionic gonadotrophin trigger on pregnancy and neonatal outcomes in Letrozole-HMG IUI cycles
por: Chen, Li, et al.
Publicado: (2023) -
Gonadotrophin releasing hormone antagonist in IVF/ICSI
por: MS, Kamath, et al.
Publicado: (2008) -
Evaluation of adenomyosis after gonadotrophin-releasing hormone agonist therapy using ultrasound post-processing imaging: a pilot study
por: Chou, Szu-Yuan, et al.
Publicado: (2020)